Bioreactor system "Ambr250"

This webinar will focus on perfusion culture, which is gaining attention for process enhancement, and will introduce examples of utilizing Sartorius solutions. The bioreactors Ambr 15, Ambr 250 HT, and Biostat STR are compatible with perfusion culture. This time, we will explain the mechanisms and operational methods using Ambr 15 and Ambr 250 HT. Additionally, our CHO cell line development service utilizes the 4Cell SmartCHO medium, which can accommodate both fed-batch and perfusion cultures, and can also be used for suitable clone selection. Through examples that combine Ambr 15 and Ambr 250 HT with the same medium, we will convey the image of its application in process development. 【Seminar Overview】 ▪ Date: July 16 (Thursday) from 15:00 (approximately 30 minutes) ▪ Format: Webinar recorded broadcast [Japanese, Free] If you are unable to participate on the day, please register first. We will send you a URL for viewing later. *We kindly ask that participants refrain from registering with email addresses other than those from your own company or organization. Thank you for your understanding.

The Ambr 250 High Throughput is a high-throughput bioreactor that accelerates process development and process characterization analysis. It enables simultaneous cultivation of up to 24 samples while incorporating automated control via a robotic arm and integration with external analytical devices. The culture containers are single-use specifications of 100-250 mL and are compatible with perfusion culture and microcarrier culture. This device has been enhanced based on customer feedback and was launched as the second generation, Ambr 250 High Throughput Generation 2, starting in 2025 to demonstrate further performance as a scale-down model. In this webinar, we will introduce the device overview and the enhanced features in Generation 2. 【Seminar Overview】 ▪ Date: October 16 (Thursday) at 15:00 (approximately 30 minutes) ▪ Method: Webinar recorded broadcast [Japanese, Free] *We apologize, but participation from companies in the same industry and email addresses other than those of your organization is not permitted. Thank you for your understanding.

Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. The development of therapeutics using viral vectors is showing strong activity, with over 30% market growth expected in the next decade. The targets for treatment are diverse, but identifying critical process parameters through process development has become an urgent issue. As the first of two webinars, we will introduce the Ambr series, a representative of process development systems in upstream processes, as well as single-use bag bioreactors up to 2000L for large-scale manufacturing, including examples of associated PAT products. *We sincerely apologize, but participation from email addresses other than those of your company or organization is not permitted. Thank you for your understanding.

Participation in this webinar has ended. If you wish to view it, please contact us, and we will send you the URL for the recorded video at a later date. Since last year, Sartorius has been presenting various proposals and suitable solutions for the challenges of "enhancing processes." In this first webinar of 2022, we will delve deeper than last year's trilogy and discuss several examples regarding cost and equipment considerations. The focus will particularly be on how to manage media that significantly impacts costs and how to design equipment. Please note that this webinar will be presented as the Japanese version of the overseas webinar "Overcoming Facility Constraints Posed by Process Intensification." ▪ Method of holding: Webinar recorded broadcast [Japanese, Free]